Mongioi LM, et al. - In this present study, the clinicians assessed the effects of dual-release hydrocortisone treatment on the glycometabolic profile and health-related quality of life of patients with adrenal insufficiency (AI). Improvement in the quality of life of patients with AI was observed through dual-release hydrocortisone treatment and it allowed a decrease of cortisol dosage administered in the absence of side effects. In patients with panhypopituitarism, the glycometabolic profile worsened.